drugset
drugset / Trial / NCT04767321

A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus

NCT04767321 ↗

Phase 1/2 Completed 15 enrolled Pharma Holdings AS CTC Clinical Trial Consultants AB · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase I/IIa, double-blind, placebo-controlled, randomised study designed to evaluate the safety, tolerability, exploratory efficacy and exposure of LTX-109 administered topically to the anterior nares in subjects with persistent carriage of S. aureus (methicillin-susceptible S. aureus \[MSSA\] and/or methicillin-resistant S. aureus \[MRSA\]).

Timeline

Start
2021-02-22
Primary completion
2021-03-23
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LTX-109 Peptide 0.25 ml Topical
Subject LTX-109 Peptide 3 % Topical

Indications

No indication recorded.